FDA revokes EUAs for hydroxychloroquine, chloroquine for COVID-19 treatment

The Food and Drug Administration today said it no longer authorizes the use of hydroxychloroquine or chloroquine as an effective treatment of COVID-19.
FDA cited serious side effects, such as cardiac adverse events, in its decision, stating that it considered results from a large trial and found neither drug to “be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks.” FDA said patients who have already been administered the drugs that were distributed under the original emergency use authorization may continue their use if deemed necessary by physicians.
Related News Articles
Headline
Healthy lifestyles and summertime fun are the themes of AHA’s new social media toolkit promoting COVID-19 vaccination and boosters. DOWNLOAD THE TOOLKIT HERE
Headline
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years…
Headline
The Food and Drug Administration authorized for marketing the first at-home over-the-counter test for COVID-19 using a traditional premarket review…
Headline
New research from the Center for Disease Control and Prevention indicates that by early fall 2022, an overwhelming percentage of American adults had…
Headline
The Centers for Medicare & Medicaid Services May 31 released regulatory changes to the COVID-19 health care staff vaccination requirements and long-term…
#HealthCareInnovation Blog
In the fall of 2021, two years into the COVID-19 pandemic in the U.S., nearly 80% of adults said they had heard “at least one of eight different false…